The global angiography equipment market is projected to reach USD 13.06 Billion by 2023 from USD 10.26 Billion in 2018, at a CAGR of 5.0%. The growth in this market is attributed to the high prevalence of diseases such as cancer and CVDs, increasing product approvals for advanced angiography techniques in the market, the large number of ongoing research activities, growing government and public-private investments, increasing number of awareness programs, and rising adoption of angiography devices due to a large number of angiography procedures performed across the globe.
Expected Revenue Growth in Angiography Equipment Market:
Browse 209 market data Tables and 47 Figures spread through 239 Pages and in-depth TOC on “Angiography Equipment Market by Product (Angiography Systems, Catheters, Guidewire, Balloons, Contrast Media) Technology (X-Ray, CT, MRA) Procedure (Coronary, Endo, Neuro) Application (Diagnostic, Therapeutic), Patient Care Setting – Global Forecast to 2027”
Download PDF Brochure:
www.marketsandmarkets.com/pdfdownloadNew.asp?id=189521618
Angiography systems segment dominated the market in 2018
On the basis of products, the market is segmented into angiography systems, angiography catheters, angiography guidewires, angiography balloons, angiography contrast media, vascular closure devices (VCDs), and angiography accessories. The angiography systems segment accounted for the largest share of the market. This can be attributed to the rising prevalence of coronary artery disease, increasing cases of blockages in blood vessels in non-coronary diseases, and technological advancements in angiography devices.
The hospitals and clinics segment dominated the market in 2018
Based on end user, the global angiography equipment market is segmented into hospitals & clinics, diagnostic & imaging centers, and research institutes. The hospitals & clinics segment accounted for the largest share of the angiography devices market. The large share of this segment can be attributed to the large number of patient pool diagnosed and treated at hospitals, the high purchasing capacity of hospitals for advanced technologies, rising number of diagnostic and therapeutic angiographic procedures, and growing awareness on timely disease diagnosis.
“Europe held the largest regional market share in 2018.”
Europe accounted for the largest share of the angiography equipment market in 2018. The large share of the European region can be attributed to factors such as the high prevalence of diseases such as cancer and CVD, the faster and easier product approval process in the region, the large number of ongoing research activities, growing government and public-private investments, increasing number of awareness programs, and rising adoption of angiography devices due to a large number of angiography procedures performed in European countries.
The Latin American region is expected to register the highest growth rate in the global angiography equipment market during the forecast period. The high CAGR of this region in this market is attributed to the rising incidence of cardiovascular disorders in this region, the rapidly increasing geriatric population in Latin American countries (particularly in Brazil and Mexico), and supportive government regulations are expected to drive the market for angiography devices in this region during the forecast period. Moreover, emerging markets have a high potential for growth in the angiography equipment market mainly due to the rising medical tourism, rising government investments and reforms to modernize healthcare infrastructure, and growing purchasing power of consumers.
Request Sample Report on Angiography Equipment Market:
www.marketsandmarkets.com/requestsampleNew.asp?id=189521618
Key Players In Angiography Equipment Market:
The major players in the global Angiography Equipment Market are F. Hoffmann-La Roche Ltd. (UK), Pfizer Inc. (US), Merck & Co (US), Novartis International AG (UK), Johnson & Johnson (US), Sanofi (France), GlaxoSmithKline Plc (UK), Amgen Inc. (US), AbbVie Inc. (US), Boehringer Ingelheim (Germany), AstraZeneca (UK), and Immatics Biotechnologies (Germany), BioNTech SE, Genmab, Gilead Sciences, NBE Therapeutics, Teva Pharmaceuticals, Bayer, and Bristol-Myers Squibb.
